7037 Background: ASTX727, is an oral formulation of the fixed dose combination of decitabine and cytidine deaminase inhibitor cedazuridine (100 mg/35 mg). We investigated whether a total oral therapy regimen of ASTX727+ven is feasible and safe. Methods: Pts aged ≥18 years (yrs) with relapsed/refractory AML (R/R) or pts with AML aged ≥ 75 or 18 -74 with comorbid conditions prohibiting intensive chemotherapy were eligible to participate (frontline-FL). Other eligibility criteria included adequate renal and hepatic function, and an ECOG performance status (PS) of≤2. ASTX727 is administered daily on days 1‐5 of each cycle and ven on days 1‐28 of the first cycle after a dose ramp up of 100-200-400 mg over 3 days (with tumor lysis prophylaxis precautions and with ven dose adjustments as needed). A bone marrow exam is performed on day 21±3 days and ven is held if blasts < 5% to allow count recovery. Cycles are repeated every 4-8 weeks and ven is administered for 21 days in subsequent cycles. Results: Between March 2021 and January 2022, 28 pts (15 FL and 13 R/R) have been treated on the study. The median age is 75 yrs (range, 47-90) with FL cohort 81 and R/R cohort 72. 9 FL pts (60%) were ≥80 and 5 (30%) 70-80 yrs. In R/R cohort 9 pts (69%) were 70-80 yrs. The median PS is 2 (range 0-3) and in the R/R cohort, the median number of prior treatments is 2 (range, 1-4). In the FL cohort 5 (33%) had normal and 6 (40%) a complex karyotype; 3 had other. In the R/R cohort, 15% had normal karyotype, 46% complex and 31% others. Mutations of note in the frontline cohort were RUNX1 (33%), ASXL1 (33%), DNMT3A (7%), TET2 (40%) and TP53 (20%). The overall response rate (ORR) including complete response (CR), CR with incomplete count recovery (CRi) and morphological leukemia free state (MLFS) in the FL cohort is 61% (4 CR, 4 CRi, 1 MLFS and 3 non-responders). 3 pts received only one day of therapy for severe adverse events unrelated to therapy (1 due to ischemic stroke, 1 septic shock and 1 debilitation) and were not evaluable for response. In the R/R cohort, the ORR was 45% (2 CR, 2 CRi, 2 MLFS with 5 non-responders and 2 not evaluable). The median number of cycles received is 2 (range, 1-5) for both cohorts. With a median follow-up of 5 months, the median survival for the FL cohort has not been reached (range, 0.6 – 7.3) and is 7.2 (range, 0.8-7.3) months for the R/R cohort. Grade 3 or higher adverse events directly attributable to therapy were mainly myelosuppression-related and included neutropenic infections in 3 (11%) and elevation of liver enzymes in 1 (4%) pt. Conclusions: Total oral therapy of ASTX727+ven is safe and feasible, particularly in the advanced elderly population, and demonstrates significant efficacy in pts unfit for chemotherapy both in the FL and R/R settings. Clinical trial information: NCT04746235.
Core binding factor (CBF) acute myeloid leukemia (AML), defined by the cytogenetic abnormalities t(8;21)(q22;q22) and inversion(16)(p13; q22)/t(16;16)(p13;q22) chromosomal changes, is considered a favorable risk AML, with an estimated 5-year overall survival (OS) rate of ≈70%. 1,2 Among patients with CBF-AML, outcomes are usually worse in t(8;21) than in inversion 16. 3 Overall, CBF-AML comprises around 10%-15% of all AML cases. 1 The addition of gemtuzumab ozogamicin (GO) to chemotherapy have improved outcomes significantly, from a 5-year OS rate of 50%-55% to 75%. 4 Non-randomized data indicate better relapse-free survival (RFS) with the addition of a second nucle-
Background: Addition of the FLT3 inhibitor midostaurin to intensive chemotherapy is the standard of care for newly diagnosed FLT3-mutated AML. Gilteritinib is a 2nd generation FLT-3 inhibitor approved for patients with relapsed/refractory (R/R) FLT3-mutated AML. We studied the combination of gilteritinib with a higher-dose araC-based regimen of Cladribine, Idarubicin, Cytarabine (CLIA) in patients with FLT3-mutated AML. Methods: Patients aged 18-65 years, fit for intensive chemotherapy, with newly diagnosed FLT3-mutated AML were enrolled. Induction was: Cladribine 5 mg/m 2 IV on days 1-5, Cytarabine 1.5-2.0 g/m 2 IV on days 1-5, Idarubicin 10 mg/m 2 IV on days 1-3 and gilteritinib on days 1-14. Consolidation consisted of up to 5 more cycles of CLIA: cladribine 5 mg/m 2 IV on days 1-3, Cytarabine 750 mg/m 2 IV on days 1-3, and idarubicin 8 mg/m 2 IV on days 1-2 with gilteritinib 120 mg continuously during cycle 2 onward. An additional cohort studied the addition of venetoclax CLIA + gilteritinib. In this cohort, venetoclax was added days 1-7 of each cycle at a target dose of 400mg daily, with dose adjustments for concomitant CYP3A inhibitors. Results: Eighteen patients were enrolled, with a median age of 56 years (range, 39-63). 15 pts (83%) had FLT3-ITD, 5 pts (27%) had FLT3 D835, and 2 pts (11%) had both. The median allelic ratio of FLT3-ITD was 0.36 (0.06-1.45) and of FLT3 D835 was 0.15 (.05-.084 Patient characteristics and outcomes are outlined in TABLE 1. Fifteen patients (83%) had diploid cytogenetics, one patient with -5, one with trisomy 8, one with Inv (16) and one patient with complex karyotype. The most commonly co-occurring mutations were: NPM1 (67%), TET2 (33%), ASXL1 (33%), and DNMT3A (33%), KDM6A (27%). Ten patients (56%) received CLIA + gilteritinib and 8 patients (44%) received CLIA + gilteritinib + venetoclax. 13 out of 18 pts (72%) achieved complete remission (CR). The rate of CR / CRi was 83%, including 8/10 pts (80%) in the CLIA + gilteritinib cohort and 7/8 pts (88%) in the CLIA + gilteritnib + venetoclax cohort. The median number of cycles to response was one (x-y). Patients received a median of 2 cycles (1-3) of therapy on protocol. The 4- and 8-week mortality rate was 6% (one patient in the venetoclax cohort, no early mortality with CLIA + gilteritinib). The most common adverse effects were: Neutropenic fever (12/18, 67%), Grade 2-3 ALT elevation in (3/18, 17%), grade 3 Headache (1/18, 6%) and grade 3 diarrhea (1/18, 6%). The median time to neutrophil ≥ 0.5 K/uL was 33 days (26-40) and 38 days (30-40) for the CLIA-gilteritinib and CLIA-gilteritinib-venetoclax cohorts. The median time to neutrophil ≥ 1 K/uL was 36.5 days (26-48) and 40 days (31-45) for the CLIA-gilteritinib and CLIA-gilteritinib-venetoclax cohorts, respectively. The median time to platelet ≥ 100 K/uL was 34.5 days (24-48) and 40 days (34-45) for 2 cohorts, respectively. Twelve of fifteen responding patients (80%) had undetectable minimal residual disease (MRD) tested by multiparameter flow cytometry by the time of response: 7/8 (88%) of the CLIA + Gilteritinib cohort and 5/7 patients (71%) of the CLIA + gilteritnib + venetoclax. Additionally, 13/15 patients (87%) had no detectable FLT3 mutation by PCR at time of response (7/8 patients (88%) of the CLIA + Gilteritinib cohort and 6/7 patients (86%) of the CLIA + gilteritnib + venetoclax cohort). The median overall survival for the entire cohort was 21.95 months (not reached for the CLIA + gilteritnib cohort and 22.4 months for the CLIA + gilteritnib+ venetoclax cohort) (Figures 1 and 2). Eleven of the 15 responding patients (73%) underwent to allogenic stem cell transplantation in CR1 (7 and 4 patients in the CLIA + gilteritnib and the CLIA + Gilteritinib + venetoclax cohort respectively). Conclusion: The combination of the FLT3 inhibitor gilteritinib to CLIA produced high rates of complete remission in patients with newly diagnosed FLT3-mutated AML. The addition of venetoclax to the backbone was associated with similar outcomes but prolonged count recovery. The combination resulted in high rates of MRD negativity by flow and molecular testing at the time of response. Further study of the combination of CLIA + gilteritinib in fit patients with newly diagnosed FLT3-mutated AML patients is planned. Figure 1 Figure 1. Disclosures Kantarjian: KAHR Medical Ltd: Honoraria; Astra Zeneca: Honoraria; Daiichi-Sankyo: Research Funding; Immunogen: Research Funding; Novartis: Honoraria, Research Funding; NOVA Research: Honoraria; Pfizer: Honoraria, Research Funding; Jazz: Research Funding; Ascentage: Research Funding; Ipsen Pharmaceuticals: Honoraria; AbbVie: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Precision Biosciences: Honoraria; Aptitude Health: Honoraria; Astellas Health: Honoraria; BMS: Research Funding; Taiho Pharmaceutical Canada: Honoraria. Alvarado: Daiichi-Sankyo: Research Funding; MEI Pharma: Research Funding; Sun Pharma: Consultancy, Research Funding; CytomX Therapeutics: Consultancy; FibroGen: Research Funding; Jazz Pharmaceuticals: Research Funding; BerGenBio: Research Funding; Astex Pharmaceuticals: Research Funding. Yilmaz: Daiichi-Sankyo: Research Funding; Pfizer: Research Funding. Pemmaraju: LFB Biotechnologies: Consultancy; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; MustangBio: Consultancy, Other; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Plexxicon: Other, Research Funding; DAVA Oncology: Consultancy; Celgene Corporation: Consultancy; Roche Diagnostics: Consultancy; Affymetrix: Consultancy, Research Funding; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Protagonist Therapeutics, Inc.: Consultancy; Sager Strong Foundation: Other; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; Clearview Healthcare Partners: Consultancy; CareDx, Inc.: Consultancy; Samus: Other, Research Funding; Daiichi Sankyo, Inc.: Other, Research Funding; Springer Science + Business Media: Other; Incyte: Consultancy; Aptitude Health: Consultancy; Cellectis S.A. ADR: Other, Research Funding; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Daver: ImmunoGen: Consultancy, Research Funding; Hanmi: Research Funding; Genentech: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Abbvie: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; Trovagene: Consultancy, Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Novartis: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Glycomimetics: Research Funding; Novimmune: Research Funding; Pfizer: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Sevier: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. Burger: TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; AstraZeneca: Consultancy; Beigene: Research Funding, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Jain: Aprea Therapeutics: Research Funding; Cellectis: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; Incyte: Research Funding; Janssen: Honoraria; Beigene: Honoraria; Servier: Honoraria, Research Funding; ADC Therapeutics: Honoraria, Research Funding; Fate Therapeutics: Research Funding; Adaptive Biotechnologies: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Pfizer: Research Funding; TG Therapeutics: Honoraria; Precision Biosciences: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Pharmacyclics: Research Funding. DiNardo: Takeda: Honoraria; ImmuneOnc: Honoraria, Research Funding; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Forma: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Foghorn: Honoraria, Research Funding; AbbVie: Consultancy, Research Funding; Agios/Servier: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding. Borthakur: Ryvu: Research Funding; Protagonist: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; ArgenX: Membership on an entity's Board of Directors or advisory committees; Astex: Research Funding; University of Texas MD Anderson Cancer Center: Current Employment; GSK: Consultancy. Ravandi: Prelude: Research Funding; AbbVie: Honoraria, Research Funding; Astex: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Taiho: Honoraria, Research Funding; Xencor: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding; AstraZeneca: Honoraria; Novartis: Honoraria. Kadia: Ascentage: Other; Genfleet: Other; Cellonkos: Other; Pfizer: Consultancy, Other; AstraZeneca: Other; Novartis: Consultancy; Sanofi-Aventis: Consultancy; Astellas: Other; Pulmotech: Other; Liberum: Consultancy; Jazz: Consultancy; Genentech: Consultancy, Other: Grant/research support; Dalichi Sankyo: Consultancy; Cure: Speakers Bureau; BMS: Other: Grant/research support; Amgen: Other: Grant/research support; Aglos: Consultancy; AbbVie: Consultancy, Other: Grant/research support.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.